

CURRICULUM VITAE

PART I: GENERAL INFORMATION

Date prepared: June 7, 2005

NAME: Myles A. Brown
OFFICE ADDRESS: Dana-Farber Cancer Institute, D730,
44 Binney Street, Boston, MA 02115
ADDRESS: 199 Ward Street, Newton, MA 02459
E-MAIL: Myles_Brown@dfci.harvard.edu
URL: <http://research.dfci.harvard.edu/brownlab>
FAX: 617-632-5417
PLACE OF BIRTH: Springfield, MA

EDUCATION:

1978 B.S. Yale University, New Haven, CT
1982 M.D. Johns Hopkins University School of Medicine, Baltimore, MD

POSTDOCTORAL TRAINING:

Internship and Residency:

1982-1983 Intern in Medicine, Brigham and Women's Hospital, Boston, MA
1983-1984 Junior Assistant Resident, Internal Medicine,
Brigham and Women's Hospital, Boston, MA
1984-1986 Senior Assistant Resident, Internal Medicine,
Brigham and Women's Hospital, Boston, MA

Fellowships:

1982-1988 Clinical Fellow in Medicine, Harvard Medical School, Boston MA
1983-1986 Research Fellow, Dana-Farber Cancer Institute, Boston MA
1986-1988 Fellow in Medical Oncology, Dana-Farber Cancer Institute
1987-1988 Visiting Scientist, Laboratory of Prof. Phillip A. Sharp, Massachusetts
Institute of Technology, Cambridge MA
1988-1990 Research Scientist, Laboratory of Prof. Phillip A. Sharp, Massachusetts
Institute of Technology, Cambridge MA

LICENSURE AND CERTIFICATION:

1986 Massachusetts Medical Licensure
1986 American Board of Internal Medicine
1989 Subspecialty Certification in Medical Oncology

ACADEMIC APPOINTMENTS

1989-1991 Instructor in Medicine, Harvard Medical School
1991-1998 Assistant Professor of Medicine, Harvard Medical School
1998- Associate Professor of Medicine, Harvard Medical School

HOSPITAL APPOINTMENTS:

1989- Associate Physician, Brigham and Women's Hospital

| | |
|-----------|--|
| 1989-1991 | Clinical Associate, Dana-Farber Cancer Institute |
| 1991-1992 | Assistant Physician, Dana-Farber Cancer Institute |
| 1992-1998 | Assistant Professor of Medicine, Dana-Farber Cancer Institute |
| 1998- | Associate Professor of Medicine, Dana-Farber Cancer Institute |
| 2002- | Chief, Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute |

PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:

| | |
|------|---|
| 1991 | Attending Physician, Adult Clinic, Dana-Farber Cancer Institute |
| 1997 | Attending Physician, Brigham and Women's Hospital |

MAJOR COMMITTEE ASSIGNMENTS:

Dana-Farber Cancer Institute:

| | |
|-----------|--|
| 1991- | Biohazard Control Committee, Member |
| 1992 | Biomedical Research Study Grant Committee, Member |
| 1992 | Women's Cancers Program Advisory Committee, Member |
| 1993- | Biohazard Control Committee, Chairman |
| 1999-2002 | Ethics Advisory Committee, Member |

American Cancer Society:

| | |
|-----------|---|
| 1996-2002 | Peer Review Committee on Carcinogenesis, Nutrition, and the Environment. Member |
|-----------|---|

National Institute of Health:

| | |
|------------|---|
| 1996, 1998 | Biochemical Endocrinology Study Section, NIDDK, |
| 2000, 2001 | ad hoc Program Project Review Committee Member |

Other:

| | |
|------------|---|
| 1994, 2002 | Army Breast Cancer Research Program, Grant Review Committee, Member, DOD |
| 1995 | Grant Review Committee, Member, National Action Plan on Breast Cancer |
| 2000-2001 | Program Committee, Member, American Association for Cancer Research |
| 2004- | Cancer Center External Advisory , Board Member, University of Cincinnati, U.C. |
| 2005- | Breast SPORE Committee, External Advisor, Baylor College of Medicine |
| 2005- | Special Conferences Committee, Member, American Association for Cancer Research |
| 2005- | United States Army Medical Research and Material Command Congressionally Directed Medical Research Programs, Era of Hope Scholars, Scientific Merit Peer Review Committee, Scientist Reviewer, DOD |

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

| | |
|-------|---|
| 1985- | American Society of Microbiology, Member |
| 1991- | American Association for the Advancement of Science, Member |
| 1995- | American Association for Cancer Research, Member |
| 1997- | American Society for Clinical Investigation, Member |
| 2002- | Endocrine Society, Member |
| 2003- | Association of American Physicians, Member |

EDITORIAL BOARD:

| | |
|-----------|--|
| 1999-2001 | Editorial Board, Member, The Prostate Journal |
| 2002- | Editorial Board, Member, Molecular Endocrinology |
| 2003- | Senior Editor, Cancer Research |

AWARDS AND HONORS:

| | |
|-----------|---|
| 1983 | Helen Hay Whitney Foundation Fellowship |
| 1988 | Clinical Investigator Award, National Cancer Institute |
| 1990 | Emil Frei III Fellowship, Dana-Farber Cancer Institute |
| 1992-1995 | Claudia Adams Barr Investigator Award, Dana-Farber Cancer Institute |
| 1992-1996 | American Cancer Society Award |
| 1995,1996 | CaP CURE Award |
| 1995-1997 | President, Boston Area Receptor Society |
| 1996 | Susan G. Komen Foundation Research Award |
| 1999 | Army Breast Cancer Program Academic Award |
| 2003 | Claudia Adams Barr Investigator Award, Dana-Farber Cancer Institute |

PART II: RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS

A. Narrative report of Research, Teaching, and Clinical Contributions

The primarily focus of the work in my laboratory at the Dana-Farber is the molecular understanding the mechanism of action of steroid hormone receptors including the estrogen and androgen receptors and their role in human cancer. We were the first to identify the p160 class of steroid receptor coactivators and to show that coregulators play an important role in the tissue and promoter selective action of steroid hormone receptors and their ligands. This work has important implications for understanding the mechanism of action of selective estrogen receptor modulators or SERMs. In addition to work in my own laboratory, I am actively involved in the Breast and Prostate Cancer Programs at the DFCI.

I am also actively involved in the teaching of post-doctoral fellows, graduate students and medical students. Together with Dr. James Decaprio I co-direct CDB211a "Biology of the Cancer Cell" at the Harvard Medical School. I have also been a tutor in the "Genetics, Development, and Reproductive Biology" (and its predecessor) course for first year students at Harvard Medical School since 1992.

My clinical activities are limited at this point to attending on the in-patient Dana-Farber/Brigham and Women's medical oncology service for 4 weeks per year and to following a very small number of general oncology patients in the out-patient clinics at the Dana-Farber.

B. RESEARCH FUNDING INFORMATION:

Past:

| | | |
|-----------|---------|----|
| 1988–1993 | NCI K08 | PI |
|-----------|---------|----|

| | | |
|----------------|--|-------|
| | “Regulation of estrogen receptor expression.” | |
| 1992-1995 | DFCI: Barr Program Small Grant “Identification and cloning of ER-associated proteins.” | PI |
| 1992-1996 | American Cancer Society Research Grant “Functions of estrogen receptor associated proteins.” | PI |
| 1992-1997 | DFCI/Sandoz: Drug Discovery Program “Discovery of ligands for new members of the nuclear receptor superfamily.” | PI |
| 1993–1994 | DFCI Butler Award Discretionary | PI |
| 1993-1995 | Dept. of Public Health, Commonwealth of Massachusetts “Transcriptional regulation of estrogen receptor in breast cancer.” | PI |
| 1994–1995 | DFCI: Women’s Cancer Program “Estrogen Receptor” | PI |
| 1995–1999 | CaP CURE Award “Mechanism of androgen receptor action in prostate cancer.” | PI |
| 1996-1997 | Susan G. Komen Foundation Research Award | PI |
| 1996–2002 | NCI/NIH: R01 CA57374 “Functions of estrogen receptor associated proteins.” | PI |
| 1998-2000 | DFCI/Novartis: Drug Discovery Program “Discovery of novel anti-androgens for the treatment of prostate cancer.” | PI |
| 1999-2002 | DoD Army Breast Cancer Program Academic Award "Estrogen Receptor Signaling in Breast Cancer" | PI |
| 2002-2004 | DFCI/Novartis: Drug Discovery Program “Discovery of novel steroid receptor ligands.” | PI |
| <u>Current</u> | | |
| 1999-2004 | NCI/NIH: P01 CA80111 Sub:0002 “Estrogen signaling in breast development and cancer” Subproject 2 of “Mechanisms of breast development and carcinogenesis.” Robert Weinberg, PI | PI |
| 2000-2005 | NCI/NIHP50 CA89393 Project 5 Dana-Farber/Harvard SPORE in Breast Cancer | co-PI |
| 2002-2006 | Army Breast Cancer Program Center of Excellence "Center for the Prevention and Treatment of ER-negative Breast Cancer" | PI |

2004-2005

DFCI/Novartis: Drug Discovery Program
“Discovery of novel steroid receptor ligands.”

PI

C. REPORT OF TEACHING:

1. Local Contributions

a. Medical School Courses

- 1992-1999 "Genetics, Embryology, and Reproduction" Harvard Medical School-6 week course, Tutor for 8 medical students
Preparation time-2 hrs/wk; Contact time-8 hrs
- 1995, 1997, 1999, 2001, 2003 CDB211a "Biology of the Cancer Cell" Harvard Medical School Course Co-Director and Lecturer for 26-40 graduate, dental, undergraduate students
Preparation time-2 hr/wk; Contact time-2 hr/wk; fall semester
- 2000 "Genetics, Development, and Reproductive Biology" Harvard Medical School-6 week course
Tutor for 8 medical students
Preparation time-2 hrs/wk; Contact time-8 hrs

b. Local and invited teaching presentations (number of attendees not recorded)

- 1990 Biotechnology Process Engineering Center, Fifth Annual Symposium, invited speaker, “Regulation of Gene Expression in Mammalian Cells.” MIT, Cambridge, MA
Preparation time-2 hrs; Contact time-1 hr
- 1994 Epidemiology Seminar, Harvard School of Public Health, invited speaker, “ Estrogen Receptor and Breast Cancer.” Boston, MA
Lecturer for fellows, residents and medical students
Preparation time-2 hrs; Contact time-1 hr
- 1995 Beth Israel Hospital Hematology/Oncology Grand Rounds, invited speaker, “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.” Boston, MA
Preparation time-2 hrs; Contact time-1 hr
- 1995 Science and Breast Cancer Seminar Series, Massachusetts General Hospital, invited speaker, “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.” Boston, MA
Lecturer for fellows, residents and medical students
Preparation time-2 hrs; Contact time-1 hr
- 1995 Hematology/Oncology Research Seminar Series, Brigham and Women’s Hospital, invited speaker, “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.” Boston, MA
Lecturer for fellows, residents and medical students
Preparation time-2 hrs; Contact time-1 hr

- 1995 Harvard Center for Cancer Prevention Workshop, invited speaker, "Causes of Cancer." Boston, MA
Lecturer for medical students, public health graduate students. Preparation time-2 hrs; Contact time-1 hr
- 2003 Massachusetts General Hospital, Cutaneous Biology Research Center Seminar, invited speaker, "Molecular Determinants of Nuclear Receptor Function." Boston, MA
Lecturer for fellows, residents and medical students
Preparation time-2 hrs; Contact time-1 hr
- 2005 Massachusetts General Hospital, Breast Cancer Seminar Series, invited speaker, "New Functions for Steroid Receptor Coregulators in Breast Cancer." Boston, MA
Lecturer for fellows, residents and medical students
Preparation time-2 hrs; Contact time-1 hr

c. Teaching Leadership Role:

- 1991- Attending Physician, Adult Clinic, Dana-Farber Cancer Institute
Trainees-fellows, residents

d. Names of Advisees or Trainees:

- 1990-1997 Fei-hua Qiu, M.D., Ph.D., Research Scientist, Department of Discovery Research, AtheroGenics, Inc., Alpharetta, GA
- 1991-1993 Isabelle Treilleux, M.D., Assistant Professor of Pathology, Centre Léon Bérard, Lyon, France.
- 1991-1996 Shlomit Halachmi, M.D., Ph.D., Staff Clinician, Department of Dermatology, Harvard University Health Services, Cambridge, MA
- 1992-1996 Adam Brufsky, M.D., Ph.D., Assistant Professor of Medicine, University of Pittsburgh Cancer Institute.
- 1992-1997 Zuoqin Tang, M.D., Associate Pathologist, Cambridge Hospital, Cambridge, MA
- 1994-1995 Rachel Meyers, Ph.D., Alnylam Pharmaceuticals, Cambridge, MA
- 1994-1997 Hong Liu, MD, Ph.D., Assistant Professor, Lurie Cancer Center, Northwestern University, Chicago, IL
- 1995-1997 Bettina Hanstein, M.D., Department of Ob/Gyn, University of Duesseldorf, Germany.
- 1995 –2000 David Chand, M.D., Infectious Disease Fellowship, Rainbow Babies and Childrens Hospital, Cleveland, OH
- 1996–1998 Ramon Rivera-Gonzalez, Ph.D., Scientist, Quality Assurance Laboratories, Amgen Puerto Rico
- 1996-2000 James DiRenzo, Ph.D., Assistant Professor, Department of Pharmacology, Dartmouth College of Medicine, Hanover, NH

1997-1998 Wongi Seol, Ph.D., Assistant Professor, Department of Biology, Sung Kyun Kwan University, Korea

1998-2000 Jaime Font de Mora, Ph.D., Research scientist, Centro De Investigación Del Cáncer, Salamanca, Spain

1999-2001 Yongfeng Shang, Ph.D., Professor and Chairman, Department of Biochemistry, Peking University, Beijing, China

1999-2004 Wenlin Shao, Ph.D., Research Scientist, Novartis, Cambridge, MA

2000-2002 Hestermann, Ph.D., Assistant Professor, Biology Department, Furman University, Greenville SC

Current Predocs:

2002- Ania Szary, M.D. Student, HST Program Harvard Medical School, DFCI

Current Postdocs:

1999- Maria Torres-Arzayus, Ph.D., Research Fellow in Medicine, DFCI

2002- Erika Keeton, Ph.D., Research Fellow in Medicine, DFCI

2002- Jason Carroll, Ph.D., Research Fellow in Medicine, DFCI

2003- Kirsten Fertuck, Ph.D., Research Associate in Medicine, DFCI

2004- Qianben Wang, M.D., Ph.D., Research Fellow in Medicine, DFCI

2004- Timothy Geistlinger, Ph.D., Research Fellow in Medicine, DFCI

2004- Susan Krum, Ph.D., Research Fellow in Medicine, DFCI

2004- Olli Janne, M.D., Ph.D., Visiting Professor of Medicine, DFCI

Regional, National or International Contributions

a. Invited presentations:

Regional:

1995 Mt. Holyoke College, invited lecture, "Coactivators in Estrogen Receptor Action." South Hadley, MA

2002 Dartmouth Medical School, Department of Pharmacology and Toxicology Seminar, invited speaker, "Coregulators and Cancer." Hanover, NH

National:

- 1993 FASEB Summer Research Conference: Cellular and Molecular Genetics: invited speaker, "Estrogen Receptor Associated Proteins." Copper Mountain, CO.
- 1996 AACR Annual Meeting: Symposium chairman, "Steroid Hormones: Breast and Prostate Cancer. Role of Transcriptional Coactivators in Steroid Receptor Function." Washington, DC
- 1996 Gordon Research Conference on Hormone Action: invited speaker, "p300 is a Component of an Estrogen Receptor Coactivator Complex.", Tilton, NH
- 1997 Frontiers in Estrogen Action, session chairman, "Steroid Receptor Associated Proteins." Key West, FL
- 1997 AACR Basic and Clinical Aspects of Breast Cancer, invited speaker, "Role of Coactivators in Estrogen Receptor Function." Keystone, Colorado
- 1998 NIDDK Workshop on Co-Activators and Co-Repressor in Gene Expression, invited speaker, "Integration and Segregation in Steroid in Steroid Receptor Signaling." Bethesda, MD
- 1999 SERMs Symposium-Implications for Prevention and Treatment of Breast Cancer, invited speaker, "The Role of Co-Regulators in Modulating ER Selectivity." Philadelphia, PA
- 2000 Indiana University Cancer Center Combined Seminar Series, invited speaker, "Dynamics of Estrogen Action." Indianapolis, IN
- 2000 Frontiers in Estrogen Action, session chairman, "Steroid Receptor Associated Proteins." Palm Beach, Florida
- 2001 AACR Annual Meeting, invited speaker, "Role of Coactivators in Cancer." New Orleans, LA
- 2002 AACR Annual Meeting, invited speaker, "Molecular Determinants of Nuclear Receptor Action." San Francisco, CA
- 2002 Keystone Symposium on Nuclear Receptors, invited speaker, "Molecular Determinants of SERM Specificity." Snowbird, UT
- 2002 New York University School of Medicine Cancer Center Seminar, invited speaker, "Coregulators, SERMs and Cancer." New York, NY
- 2002 Endocrine Society Annual Meeting, invited speaker, "Coregulator Determinants of Steroid Receptor Action." San Francisco, CA
- 2002 Gordon Research Conference on Mechanism of Hormone Action, invited speaker, "Mechanisms of Estrogen Receptor Action.", Tilton, NH
- 2002 GlaxoSmithKline NR Symposium, invited speaker, "Molecular Determinants of Nuclear Receptor Function.", Durham, NC.

- 2002 Banbury Workshop on Glucocorticoid Regulatory Mechanisms and Pathophysiology, invited participant, Cold Spring Harbor, NY.
- 2003 University of Texas, Southwestern Department of Biochemistry Seminar, invited speaker, “Molecular Determinants of Steroid Receptor Action.” Houston, TX
- 2003 University of Alabama, Birmingham Department of Pharmacology and Toxicology Seminar, invited speaker, “Coregulators and Cancer.” Birmingham, AL
- 2003 Frontiers in Estrogen Action, invited speaker, “Molecular Determinants of Estrogen Action.” Hot Springs, VA.
- 2003 Joseph and Mable Meites Lecture, Michigan State University, “Coregulators and Cancer.” Lansing, MI.
- 2003 14th Annual George Khoury Memorial Lecture, The Wistar Institute, invited speaker, “Coregulators and Cancer.” Philadelphia, PA.
- 2004 The US-Japan Workshop on “The Role of Nuclear Receptors in Carcinogenesis”, invited speaker, “Oncogenic Functions of a Steroid Receptor Coactivator.” Maui, Hawaii.
- 2004 Keystone Symposium: Nuclear Receptors: Steroid Sisters, invited speaker, “Coactivator as Oncogene.” Keystone, CO
- 2004 Androgen Action in Prostate Cancer, invited speaker, “Coregulators in AR Action.” Keystone, CO
- 2004 Yale Grand Rounds, The Julia and Patricia Kingsbury Lectureship, invited speaker, “Coregulators and Cancer.” New Haven, CT
- 2004 The American Association for Cancer Research, 95th Annual Meeting, session chairman, “Steroid Receptors and their Relation to Risk and the Progression of Cancer.” Orlando, FL
- 2004 MD Anderson Cancer Center, 57th Annual Symposium on Fundamental Cancer Research, invited speaker, “Convergence of Signaling Pathways in Oncogenic Functions of a Steroid Receptor Coactivator.”, Houston, TX
- 2004 The American Society of Andrology, 29th Annual Meeting, AUA Lecture, invited speaker, “Selective Steroid Receptor Modulators.” Baltimore, MD
- 2004 SUNY Downstate, Lecture Series; Hormone Replacement Therapy: End of a Mistake or Mistaken End?, invited speaker, “New Functions for Steroid Receptor Coregulators in Breast Cancer.” Brooklyn, NY
- 2004 John Hopkins, Sidney Kimmel Comprehensive Cancer Center, Special Symposium, Signal Transduction : from Development to Disease., invited speaker, “AIB1: from Coregulator to Oncogene.” Baltimore, MD

- 2005 Baylor College of Medicine, MCB Seminar, invited speaker, "Chromosome-Scale Analysis of Steroid Hormone Action." Houston, TX
- 2005 Keystone Symposium on Hormonal Regulation of Tumorigenesis, invited speaker, "Estrogen Receptor and its Coregulators in Estrogen Action." Monterey, CA
- 2005 Wyth 8th Frontiers in Nuclear Receptor Action Workshop, invited participant, Phoenix, AZ
- 2005 EGFR Summit 2005, invited faculty member, "AIN and IGF." Boca Raton, FL
- 2005 University of Cincinnati Cancer Center Seminar Series, invited speaker, "Chromatin Dynamics and Chromosome-Scale Analysis of Steroid Receptor Action.", Cincinnati, OH
- International:
- 1997 Xth International Conference on Hormonal Steroids, invited speaker, "Convergence of Coactivator Pathways in Steroid Receptor Signaling." Quebec City, Canada
- 2000 Second International Symposium on the Molecular Biology of Breast Cancer, invited speaker, "The Role of Coactivators in Estrogen Action." Lillehammer, Norway
- 2000 11th International Congress of Endocrinology, invited speaker, "Steroid Receptor Coactivators in Cancer." Sydney, Australia
- 2000 Hormones and Cancer 2000, invited speaker, "Dynamics of Steroid Receptor Action." Port Douglas, Australia
- 2002 Gordon Research Conference on Mammary Gland Biology, invited speaker, "Dynamics of ER Signaling." Il Ciocco, Italy
- 2003 The 2nd International Nuclear Receptor Meeting, invited speaker, "Coregulator Determinants of Steroid Receptor Function." Osaka, Japan.
- 2005 Keystone Symposium on PPAR/LXR, invited speaker, "Chromosome-Scale Analysis of Nuclear Receptor Coactivators in PPAR Action." Whistler, BC, Canada

PART III: BIBLIOGRAPHY

Original Articles:

1. Khoury G, Carter B, Ferdinand FJ, Howley P, Brown M, Martin MA. Genome localization of simian virus 40 RNA species. *J Virol* 1976;17:832–40.
2. Rosenthal L, Brown M. The control of SV40 transcription during a lytic infection: late RNA synthesis in the presence of inhibitors of DNA replication. *Nucleic Acids Res* 1977;4:551–6.
3. Ferdinand FJ, Brown M, Khoury G. Synthesis and characterization of late lytic SV40 RNA from transcriptional complexes. *Virology* 1977;78:150–61.
4. Kuster JM, Mora PT, Brown M, Khoury G. Immunologic selection against SV40 transformed cells: concomitant loss of viral antigens and early viral gene sequences. *Proc Natl Acad Sci (USA)* 1977;74:4796–800.
5. Ferdinand FJ, Brown M, Khoury G. Characterization of early SV40 transcriptional complexes: late transcription in the absence of detectable DNA replication. *Proc Natl Acad Sci (USA)* 1977;74:5443–7.
6. Goldman N, Brown M, Khoury G. Modification of SV40 T-antigen by poly ADP-ribosylation. *Cell* 1981;24:567–72.
7. Lynch DC, Zimmerman TS, Collins CJ, Brown M, Morin MJ, Ling EH, Livingston DM. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. *Cell* 1985;41:49–56.
8. Brown M, McCormack M, Zinn KG, Farrell MP, Bikel I, Livingston DM. A recombinant murine retrovirus for SV40 large T cDNA transforms mouse fibroblasts to anchorage independent growth. *J Virol* 1986;60:290–3.
9. Bikel I, Montano X, Agha, ME, Brown M, McCormack M, Boltax J, Livingston DM. SV40 small t antigen enhances the transformation activity of limiting concentrations of SV40 large T antigen. *Cell* 1987;48:321–30.
10. Brown M, Figge J, Hansen U, Wright C, Jeang KT, Khoury G, Livingston DM, Roberts TM. *Lac* repressor can regulate expression from a hybrid SV40 early promoter containing a *lac* operator in animal cells. *Cell* 1987;49:603–12.
11. Cherington V, Brown M, Paucha E, St. Louis J, Spiegelman BM, Roberts TM. Separating SV40 large T antigens transforming function from the ability to block differentiation. *Mol Cell Biol* 1988;8:1380–4.
12. Brown M, Sharp PA. Human estrogen receptor forms multiple protein-DNA complexes. *J Biol Chem* 1990;265:11238–43.
13. Kjems J, Brown M, Chang DD, Sharp PA. Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. *Proc Natl Acad Sci (USA)* 1990;88:683–7.
14. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, Brown M, Wahli W, Ozato K. Inhibition of estrogen-responsive gene activation by the retinoid X receptor B:

- Evidence for multiple inhibitory pathways. *Mol Cell Biol* 1993;13:2258–68 (author correction, vol. 15, p 3840).
15. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor associated proteins: possible mediators of hormone-induced transcription. *Science* 1994; 264:1455–8.
 16. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J Biol Chem* 1995;270:23975–83.
 17. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. *Nature* 1995; 377:451–4.
 18. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. *Science* 1996;272:123–5.
 19. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Brown M. p300 is a component of an estrogen receptor co-activator complex. *Proc Natl Acad Sci* 1996;93:11540-5
 20. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor and prostate cancer progression. *Proc Natl Acad Sci* 1997;94:3320-3323.
 21. Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancer. *Mol Cell Biol* 1997;17:1274-1280.
 22. Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. *Cancer Epidemiol Biomarkers Preven* 1997;6:189-92.
 23. Treilleux I, Peloux N, Brown M, Seargeant A. Human estrogen receptor gene promoter P1: estradiol independent activity and estradiol inducibility in ER+ and ER- cells. *Mol Endocrinol* 1997;11:1319-31.
 24. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME. Cyclin D1 stimulation of estrogen receptor transcription independent of Cdk4 activation. *Mol Cell Biol* 1997;17:5338-47.
 25. Platz E, Giovannucci E, Dahl D, Krithivas K, Brown M, Hennekens C, Stampfer M, Kantoff PW. The GGN repeat in the androgen receptor and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev.* 1998;7:379-84.
 26. Seol W, Hanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the orphan receptor SHP. *Mol Endocrinol* 1998;12(10):1551-7.
 27. Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 1998;7:1075-8.

28. Shim W-S, DiRenzo J, DeCaprio JA, Santen RJ, Brown M, Jeng M-H. Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium. *Proc Natl Acad Sci* 1999;96:208-13.
29. Hanstein B, Liu H, Yancisin M, DiRenzo J, Brown M. Functional analysis of a novel estrogen receptor beta isoform. *Mol Endocrinol* 1999;13:129-37.
30. Rebbeck TR, Kantoff PW, Krithivas K, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer penetrance by the polymorphic androgen receptor CAG repeat. *Am J Hum Genet* 1999;64:1371-77.
31. Krithivas K, Yurgalevitch S, Mohr B, Wilcox C, Batter S, Brown M, Longcope C, McKinlay J, Kantoff PW. Evidence that the CAG repeat in the androgen receptor gene is associated with the age related decline in serum androgen levels in men. *Endocrinology* 1999;162:137-42.
32. Platz E, Giovannucci E, Brown M, Cieluch C, Shepard T, Stampfer M, Kantoff P. Amplified in breast cancer-1 glutamine repeat and prostate cancer risk. *The Prostate Journal* 2000;2: 27-32.
33. Poelzl G, Kasai Y, Mochizuki N, Shaul PW, Brown M, Mendelsohn ME. Specific association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. *Proc Natl Acad Sci U S A.* 2000;97:2836-39.
34. Jones GB, Wright JM, Hynd G, Wyatt JK, Yancisin M, Brown M. Library screening allows rapid identification of bioactive enediynes. *Org Lett* 2000;2:1863-66.
35. Font de Mora, J, Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. *Mol Cell Biol* 2000;20:5041-47.
36. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Brown M, Hunter DJ. A polymorphic repeat in AIB1 does not alter breast cancer risk. *Breast Cancer Res* 2000;19:378-85.
37. Carroll, RS, Brown, M, Zhang, J, DiRenzo, J, Font de Mora, J, Black, PM. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. *Clin Cancer Res* 2000;6:3570-75.
38. DiRenzo, J, Shang, Y, Phalen, M, Sif, S, Myers, M, Kingston, R, Brown, M. BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. *Mol Cell Biol* 2000;20: 7541-49.
39. Shang Y, Hu X, Lazar MA, DiRenzo, J, Brown M. Cofactor dynamics and sufficiency in estrogen receptor regulated transcription. *Cell* 2000;103:843-52.
40. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. *Cancer Res* 2001;61:3858-62.
41. Jones GB, Hynd G, Wright JM, Purohit A, Plourde II GW, Huber RS, Mathews JE, Li A, Kilgore MW, Bublely GJ, Yancisin M, Brown M. Target-directed enediynes: designed estramycins. *J Org Chem* 2001;66:3688-95.
42. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen S, Godwin AK, Daly MB, Narod SA, Brunet J-S, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M. Modification of

BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. *Cancer Res.* 2001;61:5420-24.

43. Yahata T, Shao W, Endoh H, Hur J, Coser KR, Sun H, Ueda Y, Kato S, Isselbacher KJ, Brown M, Shioda T. Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. *Genes Dev.* 2001;15:2598-2612.
44. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers WR, Loda M, Brown M. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. *Cancer Res* 2002;62:89-98.
45. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. *Cancer Res* 2002;62:1045-49.
46. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002;11:215-6.
47. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. *Mol Cell* 2002;9:601-10.
48. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. *Science* 2002;295(5564):2465-8.
49. Shao W, Halachmi S, Brown M. ERAP140, a conserved tissue-specific nuclear receptor coactivator. *Mol Cell Biol* 2002;22:3358-72.
50. Hestermann E and Brown M. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. *Mol Cell Biol* 2003;23:7920-25.
51. Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. *Proc Natl Acad Sci U S A.* 2004;101:11599-604.
52. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. *Cancer Cell* 2004;6:263-74.
53. Febbo, P. G., Lowenberg, M., Thorner, A. R., Brown, M., Loda, M., and Golub, T. R. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. *J Urol* 2005;173:1772-77.
54. Keeton, E. K., and Brown, M. Cell Cycle Progression Stimulated by Tamoxifen-bound ER α and Promoter-Specific Effects in Breast Cancer Cells Deficient in the Corepressors N-CoR and SMRT. *Mol Endocrinol* 2005;19:1543-54.
55. Carroll JS, Liu XS, Brodsky AS, Meyer CA, Li W, Szary AJ, Eeckhoutte J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide Mapping of Estrogen Receptor Binding Reveals Long-range Regulation Requiring the Forkhead Protein FoxA1. *Cell* 2005; (in press)

56. Georgescu S, Karas R, Qing L, Li JH, Galper J, Brown M, Mendelsohn ME. Modulator Recognition Factor 1 (MRF1), an ARID-Family Member, is a Novel Co-Repressor for Estrogen Receptor α . *Mol Endocrinol* 2005; (in press)

Proceedings of Meetings:

1. Khoury G, Howley P, Brown M, Martin MA. The detection and quantitation of SV40 nucleic acid sequences using single stranded DNA probes. *Cold Spring Harbor Symposium on Quantitative Biology* 1975; 39:147-52.
2. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. *Clin Cancer Res.* 2004 Jan 1;10(1 Pt 2):327S-330S.

Reviews, Chapters, and Editorials:

1. Cherington V, Gee C, Brown M, Paucha E, Spiegelman B, Roberts TM. Analysis of the effects of polyoma and SV40 large T antigens on differentiation. In: Alt FW, Harlow E, Ziff EB, eds. *Nuclear Oncogenes*, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988.p.138-43.
2. Glass CK, Brown MA. Molecular Mechanisms of Estrogen and Thyroid Hormone Action. In: Noda, M. ed. *Molecular and Cellular Biology of Bone*, New York, NY: Academic Press; 1993.p. 257–85.
3. Brown M. Estrogen Receptor Molecular Biology. In: Henderson IC, Shapiro CL, eds. *Hematology/Oncology Clinics of North America*, Philadelphia, PA: WB Saunders; 1994; Vol 8, p. 101–12.
4. Kantoff P, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. *Biochimica et Biophysica Acta* 1998; 1378:1- 5.
5. Miner JN, Brown M. Glucocorticoid Action. In: Austen S, Burakoff SJ, et al., eds. *Therapeutic Immunology*, 2nd edition, London, UK: Blackwell Science; 2000.p. 103-06.
6. Febbo PG, Brown MA. Nuclear Receptors in Normal Prostatic Growth and Disease. In: Kantoff PW, et al., eds. *Prostate Cancer: Principles and Practice*, Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p.29-52.
7. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. *Urology.* 2002;60:(3 Suppl 1):1-6.
8. Keeton, EK, Brown, M. Coregulator Expression and Breast Cancer: Improving the Predictive Power of Estrogen Receptor alpha. [Editorial]. *Clin Cancer Res*, 2003. **9**(4):1229-30.
9. Shao, W. Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. *Breast Cancer Res.* 2004;6(1):39-52.

Clinical Communications:

1. Anderson P, Macklis J, Brown M, Ory D. Eosinophilic cerebrospinal fluid pleocytosis and cryptococcal meningitis. Ann Intern Med 1985 Aug;103(2):306-7.

Patents:

1. Kantoff PW, Brown M, Giovannucci E, inventors. Method for predicting the risk of prostate cancer morbidity and mortality. US patent 6,300,060. 2001 October 9.